Background & aims Obeticholic acid (OCA) is the second-line treatment approved for
patients with primary biliary cholangitis (PBC) and an inadequate response or intolerance to …

Obeticholic acid (OCA), a potent farnesoid X receptor agonist, was studied as monotherapy
in an international, randomized, double‐blind, placebo‐controlled phase 2 study in patients …

Patients with primary biliary cholangitis (PBC) with incomplete response to ursodeoxycholic
acid are at risk of disease progression and need additional therapy. Obeticholic acid (OCA) …

Background Obeticholic acid (OCA) was recently approved as the only on‐label alternative
for patients with primary biliary cholangitis (PBC) with intolerance or suboptimal response to …

Primary biliary cholangitis (PBC) is a rare autoimmune cholestatic liver disease that may
progress to fibrosis and/or cirrhosis. Treatment options are currently limited. The first-line …

Background The aim of this study was to evaluate the long-term efficacy and safety of
obeticholic acid for patients with primary biliary cholangitis using 3-year interim data from the …

Primary biliary cholangitis (PBC) is a chronic, progressive autoimmune liver disease that
mainly affects middle‐aged women. Obeticholic acid (OCA), which was recently approved …

Several clinical trials demonstrated that OCA treatment in PBC led to a significant decrease
in serum alkaline phosphatase, a marker for long-term survival. The US FDA-approved OCA …

Introduction: Primary biliary cholangitis (PBC) is an autoimmune disease of the liver
characterized by destruction and inflammation of the intrahepatic bile ducts. The disease …

Primary biliary cholangitis (PBC), previously known as primary biliary “cirrhosis”, is a rare
autoimmune liver disease characterized by the hallmark autoantibodies to mitochondrial …